Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose droperidol prophylaxis for PONV and perioperative QTc in gynecologic laparoscopic surgery
ChiCTR2600132312Phase 4Not yet recruiting
- Sponsor
- Quzhou People's Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of droperidol in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Quzhou People's Hospital. Primary endpoints: Cumulative incidence of postoperative nausea and vomiting within 24 hours after surgery, Incidence of significant QTc prolongation and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
droperidol
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2600132312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132312.